The methyl binding domain 3/nucleosome remodelling and deacetylase complex regulates neural cell fate determination and terminal differentiation in the cerebral cortex by Knock, E et al.
Knock et al. Neural Development  (2015) 10:13 
DOI 10.1186/s13064-015-0040-zRESEARCH ARTICLE Open AccessThe methyl binding domain 3/nucleosome
remodelling and deacetylase complex regulates
neural cell fate determination and terminal
differentiation in the cerebral cortex
Erin Knock1,4*, João Pereira2,3, Patrick D Lombard1, Andrew Dimond3, Donna Leaford1, Frederick J Livesey1,2,3
and Brian Hendrich1,3Abstract
Background: Chromatin-modifying complexes have key roles in regulating various aspects of neural stem cell biology,
including self-renewal and neurogenesis. The methyl binding domain 3/nucleosome remodelling and deacetylation
(MBD3/NuRD) co-repressor complex facilitates lineage commitment of pluripotent cells in early mouse embryos and is
important for stem cell homeostasis in blood and skin, but its function in neurogenesis had not been described. Here,
we show for the first time that MBD3/NuRD function is essential for normal neurogenesis in mice.
Results: Deletion of MBD3, a structural component of the NuRD complex, in the developing mouse central nervous
system resulted in reduced cortical thickness, defects in the proper specification of cortical projection neuron subtypes
and neonatal lethality. These phenotypes are due to alterations in PAX6+ apical progenitor cell outputs, as well as
aberrant terminal neuronal differentiation programmes of cortical plate neurons. Normal numbers of PAX6+ apical
neural progenitor cells were generated in the MBD3/NuRD-mutant cortex; however, the PAX6+ apical progenitor cells
generate EOMES+ basal progenitor cells in reduced numbers. Cortical progenitor cells lacking MBD3/NuRD activity
generate neurons that express both deep- and upper-layer markers. Using laser capture microdissection, gene
expression profiling and chromatin immunoprecipitation, we provide evidence that MBD3/NuRD functions to
control gene expression patterns during neural development.
Conclusions: Our data suggest that although MBD3/NuRD is not required for neural stem cell lineage commitment,
it is required to repress inappropriate transcription in both progenitor cells and neurons to facilitate appropriate cell
lineage choice and differentiation programmes.
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The production of differentiated neuronal cell types in
the developing brain is tightly regulated both spatially
and temporally. During the course of cerebral cortex
development, neural progenitor cells generate specific
subsets of cortical neurons in a characteristic temporal* Correspondence: erin.knock@gmail.com
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Neural progenitor cells must be able to respond to
extracellular signals at the appropriate developmental
stage in order to initiate the transcriptional programmes
specific to a particular cell lineage. Although the mo-
lecular mechanisms underlying specific lineage decisions
made by neural progenitors are not fully understood,
control of gene expression by chromatin-modifying pro-
tein complexes is likely to play a key role in enabling
neural precursors to interpret developmental cues
instructing them to execute lineage-specific transcrip-
tional programmes (reviewed in [2]).This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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produce two apical progenitors or asymmetrically to
produce one apical progenitor and one neuron or an
intermediate/basal progenitor cell [3]. Intermediate or
basal progenitor cells are found in the sub-ventricular
zone (SVZ) of the developing cortex. These progenitor
cells are capable of symmetric division to produce two
neurons and function to increase the neurogenic cap-
acity of the apical progenitors [3].
The nucleosome remodeling and deacetylation (NuRD)
complex is a multiprotein transcriptional co-repressor
complex which has been shown to control cell fate deci-
sions in a variety of developmental contexts in both plants
and animals [4,5]. The main enzymatic components of
NuRD are provided by the ATPase/nucleosome remodel-
ling component (CHD4, CHD3 or CHD5) and the class I
histone deacetylases 1/2 (HDAC1/2). Methyl-CpG binding
domain 2 (MBD2) and methyl-CpG binding domain 3
(MBD3) are mutually exclusive in NuRD [6]. However,
while MBD2-null mice are viable and fertile, MBD3 is
essential for embryonic development [7,8]. There is no
evidence that MBD3 exists or functions outside of the
NuRD complex. Biochemical purification of Mbd3 from
HeLa cells [9,10] and in embryonic stem (ES) cells (BH
Lab, PhD Theses and unpublished) confirms that the
only significant MBD3 interactions are with NuRD
components. MBD3 has been shown to be a key struc-
tural protein of NuRD, such that without MBD3, the
complex does not form [11,12]. MBD3/NuRD plays an
important role in various developmental processes,
while MBD2/NuRD (also known as Mecp1) is not es-
sential but rather plays more evolutionarily important
roles [13]. In mice, MBD3/NuRD activity is important
for developmental transitions of pluripotent cells, as
well as for appropriate stem cell homeostasis in haem-
atopoietic and epithelial development [8,12,14-17]. MBD3/
NuRD components are expressed in the developing mouse
neocortex in areas where neural progenitors reside and are
implicated in control of neural identity during neurogen-
esis [18-20]. Recently, a role for one MBD3/NuRD compo-
nent protein, CHD4, in promoting synaptic connectivity in
postnatal mouse brain has been described [21], but the
function of MBD3/NuRD during neurogenesis has not
been reported.
In this study, we report the function of the MBD3/
NuRD complex during neural development in mice.
Conditional deletion of the two main isoforms of MBD3
in the neural lineage revealed that MBD3/NuRD is ne-
cessary for PAX6+ apical progenitor cells to implement
appropriate lineage decisions. We also find that MBD3/
NuRD functions to repress the deep-layer transcriptional
programme in postmitotic neurons. In contrast to ES
cells, MBD3/NuRD is not required for lineage commit-
ment in neural stem cells but is necessary for neuralprogenitors to differentiate properly into all cell types of
the neocortex.
Results
Loss of MBD3/NuRD function results in fewer cortical
neurons
MBD3 is expressed in cells of the ventricular zone (VZ)
and SVZ at E12.5 and from E14.5 is also expressed in a
sub-population of cortical plate neurons (Figure 1A).
Embryos in which exon 1 of the Mbd3 gene had been
deleted using the Nestin-Cre transgene (conditional
knockout or cKO) showed no anti-MBD3 staining in
either of these areas from E12.5 (Figure 1A, Additional
file 1: Figure S1B). Nestin-Cre was chosen as this pro-
vides expression of Cre from early on in neural develop-
ment (prior to PAX6 expression) but would not delete
Mbd3 in very early embryonic development when Mbd3
is essential [8,22-24]. While Cre-mediated excision of
the floxed Mbd3 allele used in this study results in loss
of MBD3A and MBD3B only, no anti-MBD3 reactivity
was detectable in the brains of cKO embryos after E12.5,
indicating that MBD3C is not significantly expressed in
the developing cortex. Nervous system-specific deletion
of MBD3 resulted in a significantly smaller cerebral
cortex from approximately the mid-point of the cortical
neurogenic period (E14.5; Figure 1, Additional file 1:
Figure S1C). The size difference was only detected in the
anterior sections at E14.5 but was observed in all areas
by E16.5 which is consistent with the anterior-posterior
gradients of neurogenesis in the mouse cortex. The rela-
tive thickness of the MBD3-null cortex was significantly
thinner than that of littermate controls throughout de-
velopment and was approximately 75% of the thickness
of littermate controls at E18.5 (Figure 1B).
To determine whether this phenotype resulted from a
loss or reduction of any specific cell population, we
quantified the number of PAX6+ apical and EOMES+
basal progenitors present in mutant and wild-type (WT)
cortices. Quantification of PAX6-expressing apical pro-
genitors in the VZ at E14.5, 16.5 and 18.5 indicated no
significant difference between mutant and wild-type cor-
tices at any time point (Figure 2A,B). In contrast, MBD3
cKO cortices had significantly fewer EOMES-expressing
basal progenitor cells than WT controls at E16.5
(Figure 2C,D). We also counted the number of phos-
phorylated histone H3 (pH3)-positive cells at the apical
surface of the VZ from three non-consecutive sections
of five mice per genotype. We observed no change in
the number of cells in mitosis at the apical surface when
we compared WT and cKO mice (Figure 2E,F). When
we counted the number of non-apical pH3-positive cells
from the experiment mentioned above, we observed a
borderline significant decrease in the cortex of cKO at
E14.5 and a significant decrease at E16.5 compared to
Figure 1 Characterisation of Mbd3-mutant brains. (A) Representative MBD3 immunostaining (brown) on haematoxylin-stained coronal sections of
E12.5, 14.5, 16.5 and 18.5 embryonic wild-type (WT) and mutant (Mbd3 cKO) brains. Black arrows denote the presumptive cortical plate, and white
arrows denote the presumptive VZ. Wild-type and mutant sections were stained together on one slide, so the wild type acts as a positive control
for staining in the mutant section. Scale bar = 100 μm. (B) Mean measurements of cortical thickness from three non-consecutive coronal sections
per brain in wild-type (WT) and Mbd3 cKO) embryos. N = 3-6. *E14.5 P = 0.0192, df = 2; E16.5 P = 0.0001, df = 2; E18.5 P = 0.0001, df = 2. Error bars
represent st. dev.
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with mutant brains containing a reduced number of
EOMES+ basal progenitors at E16.5. The borderline
significant change observed at E14.5 suggests that there
may be subtle changes in cell divisions in EOMES+ basal
progenitors although we could not detect any change in
cell number at this stage.
One role proposed for EOMES-expressing basal
progenitor cells is to amplify the neurogenic output
of PAX6+ apical progenitors [3]. Therefore, fewer
EOMES+ basal progenitors would be predicted to re-
sult in reduced neuronal output and could thereby
explain the reduction in cortical thickness observed
in MBD3-mutant embryos. To test this hypothesis,differentiated cell output was measured over a 24-h
period by injecting pregnant dams with a single dose
of bromodeoxyuridine (BrdU) at E13.5 or E15.5 and
examining the embryos 24 h later. Differentiated cells
generated during the BrdU pulse were defined as those
cells showing strong staining for BrdU label but not
expressing PAX6 and which had migrated outside the VZ
and SVZ. This experiment indicated that while cKO
embryos produced normal numbers of differentiated
cells between E13.5 and E14.5, they show a signifi-
cantly reduced output of differentiated cells between
E15.5 and E16.5 (Figure 3A,B). The differentiated cells
in this experiment could be either EOMES+ basal pro-
genitors, neurons, glia or oligodendrocytes. Glia and
Figure 2 Mbd3-deficient embryonic brains show reduced production of EOMES+ basal neural progenitors and reduced neural output.
(A) Representative immunostaining of E14.5, E16.5 and E18.5 coronal brain sections for PAX6. (B) Quantification of stained cells per 100 μm of cortical
length. (C) Representative immunostaining of E14.5, E16.5 and E18.5 coronal brain sections for EOMES with DAPI counterstain. (D) Quantification of
stained cells per 100 μm of cortical length. N = 3 to 6 *P = 0.0100, df = 2. (E) Representative immunostaining of E14.5 and E16.5 coronal brain sections
for phosphorylated histone H3 (pH3). White arrows indicate the positions of apical and non-apical pH3+ cells. (F) Quantification of the number of apical
surface pH3+ cells at E14.5 and E16.5 per 100 μm of cortical length, N = 3. (G) Quantification of the number of non-apical surface pH3+ cells at E14.5
(P = 0.067, df= 2) and at E16.5, N = 3, *P = 0.029, df= 2. Error bars represent st. dev. Scale bar = 100 μm.
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Figure 3 Mbd3cKO mice produce fewer differentiated cells. (A) Pregnant mice were injected with a single pulse of BrdU 24 h prior to examination
of the embryos at the indicated time points. Differentiated cell output was defined as the number of strongly BrdU (++)/PAX6− cells outside the VZ
produced in that 24-h period. Representative immunostaining of E14.5 and E16.5 coronal brain sections for BrdU (red) and PAX6 (green). The white
line represents the presumptive boundary between the VZ and outside the VZ (non-VZ). The bottom panels are a magnified image of the boxed
area in the above picture. The green, red and yellow arrows point out a PAX6 only +, strong BrdU only + and PAX6/BrdU double-positive cell,
respectively. (B) Quantification of the number of differentiated neurons produced in 24 h. Scale bar = 100 μm; N = 3 to 6, *P = 0.0134, df = 2. Error
bars represent st. dev. Scale bar = 100 μm.
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development (E18.5 on), so we have excluded these as
being the cells we observe. Given that the numbers of
neurons produced is much higher than the number of
EOMES+ basal progenitors and that we are looking
largely in the cortical plate, we (like others [25]) have
made the assumption that the majority of cells we are
counting are neurons. This finding is consistent with
the predicted reduction in neurons generated from the
reduced number of EOMES+ basal progenitor cells in
the MBD3-null cortex.
Altered progenitor cell proliferation in MBD3/NuRD-mutant
cortices
Reduced numbers of EOMES+ basal progenitor cells
could result from reduced production by PAX6+ apical
progenitor cells, increased cell death in this popula-
tion or from a change in the balance between self-
renewal and differentiation in this population. We could
detect no difference in the number of cells undergoing
apoptosis between wild-type and mutant embryos at E14.5,
16.5 or 18.5 as judged by staining with an antibody against
the cleaved (activated) form of caspase-3 (Additional file 2:
Figure S2). However, the VZ of the MBD3-null cortex
showed reduced numbers of Ki67-positive cells at E16.5,but not at E14.5, emphasizing the presence of fewer total
cycling progenitor cells in mutant brains between E15.5
and E16.5 (Figure 4A,B). This reduction in cycling cells,
which is not associated with an increase in apoptosis,
could be due to an increased frequency of cells exiting
the cell cycle. To test this possibility, cortices from em-
bryos that had been labelled with BrdU for 24 h were
visualised for both BrdU incorporation and Ki67 re-
activity. Those cells that had divided in the previous
24 h and subsequently exited the cell cycle would have
incorporated BrdU, but would not stain for Ki67.
Whereas a similar number of cells showed cell cycle
exit at E14.5, by E16.5, the VZ of cKO embryos con-
tained significantly more Ki67-negative cells that had
taken up BrdU in the previous 24 h (Figure 4C,D).
The observed increase in cell cycle exit in the VZ
could be the result of reduced numbers of EOMES+
basal progenitors (Figure 2) or an alteration in the cell
cycle of PAX6+ apical progenitors. To examine the
proliferation rate of the PAX6+ apical progenitor cell
population at E16.5, we counted the percentage of
PAX6 + BrdU+/BrdU total cells in the VZ using the sam-
ples described in Figure 3. These data show that fewer
PAX6+ progenitors in Mbd3cKO embryos (4.1 ± 3.0 st.
dev.) incorporated BrdU in the VZ between E15.5 and
Figure 4 Fewer Mbd3-deficient PAX6+ apical progenitors divide between E15.5 and E16.5. (A) Representative immunostaining of E14.5 and E16.5
coronal brain sections for Ki67. The white lines indicate the presumptive boundary between the VZ and outside in the VZ (non-VZ). (B) Quantification of
the number of Ki67+ cells in the VZ per 100 μm of cortical length. N = 3 to 6, *P= 0.0199, df = 2. (C) Representative immunostaining of E14.5 and E16.5
coronal brain sections for BrdU (red) and Ki67 (green). The bottom panel is a magnified image of the boxed area in the above picture. (D) Quantification
of the percentage of BrdU+/Ki67− cells in the VZ negative for Ki67 per 100 μm of cortical length (right panel). N= 3 to 6, *P = 0.0015, df= 2. Error bars
represent st. dev. Scale bar = 100 μm.
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dev., N = 3 to 5, *P = 0.0200, df = 2) as measured by
the percentage of BrdU + PAX6+/total BrdU cells in
the VZ at E16.5 per 100 μm of cortical length. To
measure the cell cycle distribution of the PAX6+
progenitors, we used flow cytometry on single PAX6+
cells isolated from E14.6 and E16.5 cortices (Additional
file 3: Figure S3). We did not observe any change in cell
cycle at E16.5 (Additional file 3: Figure S3A); however,
at E14.5 Mbd3cKO, a higher percentage of PAX6+
progenitors were in S phase and fewer were in G1
(Additional file 3: Figure S3B). This is consistent with
previously published reports showing that knockdown
of the Mi-2β subunit of MBD3/NuRD results in aprolonged S-phase [26] and that Mi-2β regulates G1/S
transition [27].
Between E15.5 and 16.5, most divisions of PAX6+
apical progenitors are asymmetric: producing one neuron
and one daughter progenitor cell, thereby maintaining
the size of the PAX6+ apical progenitor population while
still allowing for neuronal production [28]. Our data are
consistent with a reduction in the rate of asymmetric di-
visions of PAX6-expressing apical progenitors, resulting
in a decrease in neuronal production without a change in
the size of the progenitor pool (Figures 2 and 5). To-
gether, these data suggest an increase in the fraction of
neural progenitor cells exiting the cell cycle in the ab-
sence of MBD3. Notably, this premature cell cycle exit
Figure 5 PAX6+ progenitors exiting the cell cycle result in decreased numbers of basal progenitors and neurons. This graphic illustrates how
three representative PAX6+ apical progenitors in WT (left) and Mbd3cKO (right) mice make cell fate decisions over time. In the Mbd3cKO mice,
a PAX6+ cell which exits the cell cycle without terminal differentiation into a neuron (far right) reduces the production of EOMES+ basal
progenitors and neurons. This effect is small at first (E14.5) but increases in severity over time (E18.5). Note that in both WT and Mbd3cKO, the
numbers of apical progenitors decreases over time, as expected, but at each time point, the numbers are comparable between the two groups.
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ation of these progenitor cells, as they fail to migrate
from the VZ (Figure 4C).
Loss of MBD3 results in alterations in the proportions of
different cortical neuronal subtypes
To quantify the timing of appearance and the relative
numbers of different cortical neuronal types, the expres-
sion of transcription factors specifically expressed in
different neuronal populations was analysed in wild-type
and mutant embryos at three stages of cortical develop-
ment (E14.5, E16.5 and E18.5). Deep-layer neuron tran-
scription factors included TBR1 (layer 6) and BCL11B/
CTIP2 (layer 5), and upper-layer neurons were identified
by expression of SATB2, CUX1 and BRN2 (Figure 6
and 7A, Additional file 4: Figure S4). MBD3 cKO cortices
contained normal proportions of TBR1 and BCL11b-
expressing deep-layer neurons at E14.5 (Figure 6A,B).
However, at E16.5, the MBD3 cKO cortex contained
significantly more TBR1 and BCL11B-expressing cells and
significantly fewer SATB2-expressing cells than WT con-
trols (Figure 6C,D). In contrast, we saw no defects in the
earliest born neuronal population (layer 1), as judged by
Reelin staining, at E16.5 (Additional file 5: Figure S5). By
E18.5, the MBD3 cKO cortex continued to have more
BCL11b expressing cells but only showed a reduction
in the number of upper-layer cells expressing BRN2
(Figures 6E,F and 7A). These data support previous studies
[19,20] suggesting that MBD3/NuRD may be involved in
suppressing BCL11B in SATB2 expressing neurons. To
confirm this finding, we counted the %SATB2 and BCL11B
double-positive cells/total SATB2-positive cells. As
expected, Mbd3 cKO mice at E16.5 had a signifi-
cantly higher %SATB2+ BCL11B+/SATB2+ cells per
100 μm cortex compared to WT mice (WT: 35.1 ± 14.6 st.
dev., cKO: 63.5 ± 24.8 st. dev., P = 0.0006, N = 4, df = 3).In addition to a reduced number of cortical neurons,
MBD3-mutant brains also exhibited a defect in cortical
lamination. While wild-type E16.5 and 18.5 brains con-
tained the distinct populations of BCL11B-high (layer 5)
and BCL11B-low (layer 6) expressing cells associated
with proper cortical architecture [29], cKO cortices con-
tained only a BCL11B-high expressing population (white
arrows in Figure 6C,E). Further, while normally lami-
nated wild-type cortices had distinct layers of cells neu-
rons expressing singly either BCL11B (layer 5), SATB2
(layer 2/3) or TBR1 (layer 6) (Figure 6) [3,29], no such
organisation was evident in mutant cortices. Instead,
cells expressing the different markers were intermingled
(coloured lines in Figure 6C,E). Although MBD3 is dis-
pensable for TBR1 and BCL11b-expressing early neur-
onal production, proper differentiation of later, SATB2
and BRN2-expressing upper-layer neurons and appropri-
ate cortical lamination require the function of MBD3/
NuRD.
Deep-layer neuron differentiation is extended in the
MBD3-null cortex
Given the alterations in the relative numbers of BCL11b
and SATB2/BRN2 expressing neurons in the MBD3-null
cortex during cortical development, the timing of the
production of upper-layer neurons was assessed by BrdU
birthdating. Around E13.5, neurogenesis switches from
deep-layer neuron production to upper-layer neuron
production [30]. Therefore, neuronal birthdates were
studied in embryos labelled at E13.5 with a single dose
of BrdU and analysed at E18.5 for expression of tran-
scription factors specific to upper-layer (BRN2 and
SATB2) and deep-layer (TBR1) neurons (Figure 7). Con-
sistent with the decrease in total numbers of BRN2-
expressing upper-layer neurons in the MBD3-null cortex
E18.5 (Figure 6F), a significantly smaller proportion of
Figure 6 (See legend on next page.)
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Figure 6 Altered neuron production and cortical layering in Mbd3-deficient brains. Representative immunostaining of coronal brain sections at
E14.5 (A), E16.5 (C) and E18.5 (E) for TBR1 (blue, layer 6), BCL11B (green, layer 5) and SATB2 (red, layers 2 to 4). Quantification of the number of
stained cells per 100 μm cortical length at E14.5 (B), E16.5 (D, *P = 0.0040, df = 2 [TBR1]; P = 0.0220, df = 2 [BCL11b]; P = 0.0010, df = 2 [SATB2]) and
E18.5 (F, *P = 0.0100, df = 2 [BCL11b]; P = 0.0090, df = 2 [BRN2]). Scale bar = 100 μm; N = 3 to 6. Error bars represent st. dev. White arrows in (B) and
(C) point to the BCL11B high and low expressing cells in WT brains, while in cKO brains, only the BCL11B high-expressing cells are present. Red,
green and blue bars in (C) and (E), WT merged images indicate distinct layers of cortical neurons present based on the staining. These layers do
not appear or are reduced in the Mbd3 cKO brains (yellow bars, (C) and (E) merged images).
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neuronal marker BRN2 in MBD3-deficient brains
(Figure 7A, %BRN2 + BrdU+/BrdU+ in cortical plate
per 100 μm of cortical length: WT: 50.6 ± 16.4 st. dev.,
cKO: 29.9 ± 10.5 st. dev., *P = 0.0016, df = 2). Further, an
increased proportion of these younger neurons express
both the deep-layer marker TBR1 and upper-layer marker
SATB2 (Figure 7B,C). These data indicate that more neu-
rons born at E13.5 in the MBD3-null cortex do not have a
well-defined cortical identity compared with their WT
counterparts. The co-expression of TBR1 and SATB2 is
consistent with aberrant terminal differentiation of later
born neurons, rather than a simple extension of the period
of deep-layer genesis by progenitor cells.
Regulation of neurogenic gene expression programmes
by the MBD3/NuRD complex
MBD3 is a structural component of NuRD, a transcrip-
tional co-repressor complex. We therefore expected that
the phenotypes observed in cKO mice would arise from
failure to properly regulate gene expression. In order
to generate a profile of MBD3/NuRD-dependent gene
expression in neural progenitors during development,
whole-genome expression analysis was carried out on an
enriched population of progenitor cells laser capture mi-
crodissected from the VZ of WT and mutant cortices at
E12.5, E14.5 and E16.5. Embryonic day 12.5 is prior to
the emergence of overt phenotypes and was expected to
yield primary gene misexpression events in cortical pro-
genitor cells. By E16.5, the mutant phenotypes were fully
apparent and thus would be expected to display both
primary and secondary gene misexpression events. Con-
sistent with our previous work in ES cells, primary gene
expression changes in the absence of MBD3 are subtle,
that is, less than fourfold (ArrayExpress accession num-
ber E-MTAB-2778) [17,31].
To get a picture of how gene expression patterns
change over the neurogenic period of brain develop-
ment, we compared gene expression data across all three
developmental time points in wild-type and mutant
embryos using the short time-series expression miner
(STEM) programme [32]. This analysis resulted in the
identification of 16 different gene expression profiles
that were significantly overrepresented in our expression
data (see Figure 8). Four of these 16 profiles show themutant samples behaving similarly to wild-type samples
(Clusters 6, 29, 43 and 20). The remaining 12 profiles all
show some degree of difference between wild-type and
mutant brains. These profiles indicate that, like in ES
cells, MBD3/NuRD does not simply function as an on/
off regulator of gene expression during neural develop-
ment but is important for maintaining levels of expres-
sion to within a particular range as transcriptional
programmes are activated/deactivated during neural
development [17,33].
Between E12.5 and E16.5, the principal output of the
neurogenic programme is neuronal, and concordantly,
progenitor cells will show some expression of genes
involved in neuronal specification. By E16.5, this
programme begins to switch from predominantly neural
production towards glial cell production [34], which is
associated with a decrease in expression of neurogenic
genes. Clusters 35 and 39 both depict gene expression
patterns in wild-type samples consistent with this sce-
nario, where genes show increased expression from
E12.5 to E14.5, but then decreased expression by E16.5
(Figures 8 and 9A, gene lists in Additional file 6:
Table S1 and Additional file 7: Table S3). However, the
expression patterns of genes in these clusters differ in
mutant cells. Cluster 39 genes are expressed at an ele-
vated level at all stages, possibly indicating a lack of tran-
scriptional control of these genes. Cluster 35 genes show
normal increase in expression from E12.5 to E14.5, but
instead of then decreasing again by E16.5, the expression
of these genes remains high at E16.5. This lack of proper
expression only at E16.5 indicates a specific failure to
maintain the appropriate levels of gene expression in re-
sponse to developmental cues, rather than a general lack
of regulation, as with Cluster 35 genes. Cluster 35 shows
a highly significant enrichment for genes associated
with gene ontology (GO) terms involving neurogenesis
(Additional file 8: Table S2, P = 1.91 × 10−4) consistent
with the peak and decline of neurogenesis from E12.5 to
16.5. Cluster 39 shows a less significant enrichment of
genes associated with neurogenesis (P > 0.01) but rather
shows enrichment for genes involved in cytoskeleton
organisation (P = 6.99 × 10−4) and chromatin organisation
(P = 2.7 × 10−3) (Additional file 9: Table S4). This pattern
of gene expression identified in Cluster 35, characterised
by a failure to appropriately decrease neurogeneic gene
Figure 7 (See legend on next page.)
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Figure 7 Failure of proper cortical neuron specification in the absence of MBD3. Pregnant mice were injected with BrdU once at E13.5 and the
embryos examined at E18.5. (A) Representative immunostaining of E18.5 coronal brain sections for BrdU (red) and upper-layer neuronal marker
BRN2 (white). (B) Representative immunostaining of E18.5 coronal brain sections for BrdU (red), TBR1 (green) and SATB2 (white). (C) Quantification
of the percentage of cortical plate BrdU+ cells which are also positive for TBR1 (*P = 0.0210, df = 2) or positive for both TBR1 and SATB2 (*P = 0.0016,
df = 2) per 100 μm of cortical length. The white lines indicate the presumptive lower boundary of the cortical plate. Scale bar = 100 μm; N = 3 to 6.
Error bars represent st. dev.
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brains, implicates MBD3/NuRD function in the execu-
tion of the neural-to-glial developmental switch.
The expression of some neurogenic bHLH transcrip-
tion factors has been shown to peak at the height of
neurogenesis (E14.5) and their downregulation is neces-
sary for gliogenesis to begin [29,35,36]. One such tran-
scription factor, Nhlh1, was included in Cluster 35 and
was also in the list of genes upregulated in E16.5 mutant
brains (ArrayExpress accession number E-MTAB-2778).
To verify this gene expression pattern, we determined
the expression patterns of four neurogenic bHLH tran-
scription factors, Nhlh1, Nhlh2, NeuroD1 and NeuroD2,
over the course of neurogenesis in progenitors from WT
and cKO embryos by quantitative reverse transcriptase
polymerase chain reaction (qRT-PCR) (Figure 9B). In
both WT and Mbd3 cKO brain samples, all four genes
show a peak of expression at E14.5 and a subsequent
reduction in expression by E16.5. This indicates that, in
the absence of MBD3/NuRD activity, neural progenitors
are capable of responding to the developmental signals
promoting expression of these genes at E12.5 and are
also able to respond to signals that result in a reduction
of gene expression by E16.5. The expression levels of
Nhlh2 are elevated at E14.5 in mutant samples com-
pared to those seen in wild-type samples, suggesting that
disruptions in neurogenesis may begin even before we
are able to detect the phenotype. Additionally, despite
three of the four genes showing a reduction of expres-
sion after E14.5, all four genes remain expressed at ele-
vated levels at E16.5 in the absence of MBD3/NuRD
activity. Chromatin immunoprecipitation (ChIP) ana-
lyses of dissected cortices at E14.5 and E16.5 showed
that Mbd3 is indeed associated with predicted regulatory
regions in all four of these loci in wild-type embryos at
both time points, consistent with direct regulation of
these neurogeneic genes by the MBD3/NuRD complex
(Figure 9C). Thus, despite apparently being able to re-
spond to inductive signals, a lack of MBD3/NuRD activ-
ity results in overexpression of neurogenic factors at
later stages of neural development.
Downregulation of the neurogenic gene expression
programme is normally associated with activation of
genes important for initiation of gliogenesis during nor-
mal brain development, with the peak of gliogenesisoccurring in early postnatal stages [34]. Importantly, his-
tone deacetylase activity has been shown to be important
for this neurogenic to gliogenic switch [37]. Clusters 28
and 29 identify two sets of genes that show little change
between E12.5 and E14.5, but activation by E16.5
(Figure 9D, gene lists in Additional file 10: Table S5 and
Additional file 11: Table S7). However, for the Cluster 28
genes, there is a failure to increase expression levels at
E16.5 in the mutant brains. Included in this cluster are
genes implicated in glial cell development, including
Gfap [38] and Neurod4 [39] (Additional file 12: Table S6,
GO analysis found no significant enrichment of terms in
cluster 29). Reduced expression of these genes in E16.5
mutant brains was subsequently verified by qRT-PCR
(Figure 9E). E18.5 mutant brains displayed a consider-
able reduction in cells expressing the glial cell marker
S100β compared to wild-type brains (Figure 9F), consist-
ent with a defect in gliogenesis in Mbd3-deficient mice.
As these mice died at birth, prior to the peak of glial cell
production, it was not possible to determine whether
this defect in gliogenesis seen at E18.5 was due to a
failure or a delay in gliogenesis. Nevertheless, these data
support the conclusion that MBD3/NuRD activity func-
tions to ensure the successful execution of developmen-
tal transitions during mammalian neurogenesis.
Discussion
Neural development proceeds in a regimented fashion
during mammalian development, with different cell
types being produced in a strict temporal order [1]. Each
cell type is specified by a distinct transcriptional
programme such that maintaining correct expression
levels of specific transcriptional programmes is essential
for proper execution of each distinct developmental
transition. Here, we use genetic analyses to show that
transcriptional modulation by the MBD3/NuRD complex
is essential for the proper execution of a number of devel-
opmental transitions during mammalian neurogenesis.
In ES cells, the NuRD component protein MBD3 is
dispensable for self-renewal but plays an important role
during lineage commitment [12]. In contrast, during
neurogenesis, MBD3 is required neither for proliferation
nor differentiation of neural progenitor cells during
embryonic development, but rather ensures proper exe-
cution of lineage-determination programmes. This is
Figure 8 Total output from the STEM programme. Significant clusters identified by STEM analysis. For each panel, the expression in wild-type embryos is
shown in blue on the left and in mutant embryos in red on the right. Developmental time (E12.5, E14.5 and E16.5) is plotted on the x-axis and expression
levels on the y-axis in arbitrary units. For each cluster, the data are plotted along the x-axis as WT12.5, WT14.5 and WT16.5 (blue) and cKO12.5, cKO14.5
and cKO16.5 (red).
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function in other somatic stem cell types [14,16].
Our observations also indicate that fewer PAX6+ apical
progenitors are dividing at later stages in Mbd3 cKO
brains. We cannot exclude the possibility that the same
number of PAX6+ apical progenitors are dividing butwith an increase in cell cycle length, although the
decreased neurogenesis and cell cycle profiles at E16.5
argue against this. Interestingly, despite equal numbers of
PAX6+ progenitors going through cell cycle (at any stage,
Figures 3A,B and 4), the cell cycle distribution is abnor-
mal at E14.5. Based on this observation, we speculate that
Figure 9 (See legend on next page.)
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Figure 9 MBD3/NuRD modulates gene expression patterns during mammalian neurogenesis. (A) Expression of genes found in clusters 35 and 39
are plotted individually for wild-type (left) and Mbd3 cKO (right) samples. (B) Relative expression of indicated genes in WT and mutant progenitors at
E12.5, E14.5 and E16.5. In all cases, expression values are plotted relative to WT expression at E12.5. N = 3 to 4. For wild-type vs. mutant samples at E14.5
for Nhlh2 *P = 0.0066, df = 2. For wild-type vs. mutant samples at E16.5 *P = 0.0032, df= 2 (Nhlh1); P = 0.0002, df= 2 (NeuroD1); P = 0.0403, df = 2 (Nhlh2);
P = 0.0001, df= 2 (NeuroD2). (C) Chromatin immunoprecipitation (ChIP) was performed using an anti-Mbd3 antibody or rabbit IgG control in wild-type
(WT) and conditional knockout (KO) cortices at E14.5 and E16.5. Immunoprecipitates were probed with primer pairs (listed in Table 3) located across
the indicated genes and plotted as percentage of input (y-axis; error bars represent st. dev.). Numbers across the x-axis indicate distance relative to the
transcription start site for indicated genes. Gene structure is shown below the graphs: white boxes represent non-coding regions, blue boxes represent
coding regions, and green boxes indicate the presence of putative enhancer regions based upon histone ChIP data available on mm9 from the UCSC
genome browser. (D) Expression of genes found in clusters 28 and 29 are plotted individually for wild-type (left) and cKO (right) samples. (E) Relative
expression of indicated genes in wild-type and mutant brain samples from E16.5. N = 3; *P = 0.0004 (NeuroD4), P = 0.0026 (S100β), P = 0.0001 (Gfap),
df = 2; error bars represent st. dev. (F) Representative immunostaining of E18.5 coronal brain sections for S100β (red). White arrow indicates a rare,
positively stained cell in the Mbd3 cKO sample Scale bar = 100 μm at 200× magnification and 50 μm at 630× magnification.
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which leads to more cells dropping out of cell cycle by
E16.5.
During normal neurogenesis, apical progenitor cells
lengthen their cell cycle and switch from primarily sym-
metric cell divisions to primarily asymmetric divisions.
The asymmetric divisions produce both basal progenitors
and neurons. Our observations of fewer BrdU+/PAX6+
apical progenitors and more BrdU+/Ki67− cells indicate
that the PAX6+ apical progenitors are unable to respond
to the signals regulating symmetric vs. asymmetric divi-
sions. They instead drop out of cell cycle and fail to pro-
duce sufficient EOMES+ basal progenitors and neurons
by asymmetric divisions. This is supported by our observa-
tion that mutant cortices show evidence of increased cell
cycle exit after E15.5 without a subsequent increase in the
number of differentiated neurons (Figures 3B and 4).
Rather, lack of MBD3 resulted in decreased numbers
of both EOMES+ basal progenitors and neurons by
E16.5. The result of this is illustrated in Figure 5. In
WT mice, PAX6+ progenitors increase their asym-
metric divisions over time, producing EOMES+ basal
progenitors and neurons leading to an increase in
the number of neurons while decreasing the size of
the progenitor pool (left panel). Early cell cycle de-
fects in Mbd3 cKO PAX6+ progenitors leads to more and
more cells exiting cell cycle without differentiating. While
the number of PAX6+ progenitors still decreases over time,
as in WT, there is no corresponding increase in EOMES+
basal progenitors and neurons (right panel).
MBD3 is expressed in a subpopulation of cortical plate
neurons, the position of which indicates that it is
primarily expressed in upper-layer neurons (Figure 1A).
Without MBD3, proper specification of SATB2- and
BRN2-expressing upper-layer neurons is compromised
(Figure 6). These observations are in agreement with
previous studies reporting that MBD3/NuRD subunits
interact with the transcription factor SATB2 in order to
repress expression of Bcl11b and thereby allow thetransition between deep-layer and upper-layer neuron
production [19,20]. Our data support this conclusion
and suggest that, in addition to producing fewer neu-
rons, the superficial neurons that are produced co-
express deep-layer and upper-layer neuronal markers
(Figure 7). That accounts for the increased numbers of
deep-layer marker expressing cells we observed (Figure 6).
Together, these data support previously reported roles for
the MBD3/NuRD complex in maintaining distinct deep
and upper neuronal layers [19,20].
Analysis of global gene expression patterns in neural
progenitors from E12.5 to E16.5 provided further evi-
dence for MBD3/NuRD’s involvement in regulating de-
velopmental transitions in the brain. It is notable that
the genes we see expressed in our study are not those
which are normally detectable at the protein level in
neural progenitors. Although we were able to enrich for
neural progenitors using the laser capture microdissec-
tion technique, we cannot exclude the possibility that
some immature or mature neurons were also captured
during this procedure. Nevertheless, unbiased clustering
of gene expression patterns revealed 12 different scenar-
ios in which gene expression changes over three
developmental time points occur aberrantly in Mbd3-
deficient embryos. This indicates that neural progenitors
can respond to the developmental cues regulating both
activation and repression of transcription in the absence
of a functional MBD3/NuRD complex. However, despite
showing some reduction in expression levels between
E14.5 and E16.5, in the absence of MBD3/NuRD activity,
the expression levels of some proneural genes are not
reduced to wild-type levels at E16.5. Our observation that
MBD3/NuRD directly regulates these genes (Figure 9B
and C) is consistent with a recent study showing that
CHD4 (an MBD3/NuRD complex component) directly
regulates Nhlh1 in the adult mouse cerebellum [40].
Unbiased clustering also identified a set of genes that
fails to be appropriately activated at E16.5, including a
number of genes indicative of a gliogenic transcriptional







12.5 25 12.5 25 20.8 24
14.5 25.9 25.9 14.8 22.2 27
15.5 50 25 12.5 12.5 16
16.5 17.5 35 29.1 14.6 57
17.5 36.4 18.2 22.7 22.7 22
Postnatal 28.4 40.8 29.6 0.8a 250
aAll N-Cre:Mbd3Flox/Flox mice born live were found dead within 24 h after birth.
Genotypes of pups and embryos produced from N-Cre(Flox/+) × (Flox/Flox)
intercrosses recovered at indicated time points.
Knock et al. Neural Development  (2015) 10:13 Page 15 of 20programme. Mbd3 cKO mice die at birth, so we were
not able to completely assess gliogenesis in this system.
However, decreased staining for the early gliogenic
marker S100β at E18.5 in mutant brains and reduced ex-
pression of genes associated with gliogenesis are consist-
ent with a role for MBD3/NuRD in regulating the
neurogenic to gliogenic switch. Therefore, while we see
no evidence that the persistent expression of the pro-
neural genes prolongs neurogenesis, it may be impeding
the switch to gliogenesis.
In ES cells, the MBD3/NuRD complex controls the dy-
namic range of gene expression, the function of which is
to maintain cells in a state that is competent to respond
to the presence or absence of specific differentiation
cues [17,41,42]. Our gene expression analyses are con-
sistent with MBD3/NuRD functioning similarly in neural
cells. When comparing gene expression in wild-type and
cKO brains, we find significant misexpression of rela-
tively few genes and the level of gene expression changes
are very modest (<fivefold). In contrast, loss of the PRC2
component protein EZH2 in cortex resulted in misex-
pression of more than 1,000 genes [25].
Conclusions
We propose that MBD3/NuRD acts in the developing
brain to keep the levels of pro-neurogenic gene tran-
scription in check so that cells can properly respond to
developmental cues and, when appropriate, switch to a
different transcriptional programme. In the absence of
MBD3/NuRD we find that cells are able to respond to
developmental signals, but are unable to appropriately
down-regulate expression of genes that would be in-
appropriate in the new lineage to be specified (for
example, Figures 7C,D and 9). Consequently, progenitor
cells are unable to properly execute their normal lineage
decisions, resulting in alterations in progenitor cell
homeostasis and an inability to generate the normal
spectrum of neuronal subtypes. Notably, this activity for
MBD3/NuRD in down-regulating gene expression dur-
ing developmental transitions has previously been de-
scribed in early mouse development, in ES cells, in
nematodes and in plants [8,17,43,44].
Methods
Mice
All mouse husbandry and experimentation was approved
by the Animal Welfare and Ethical Review Body,
University of Cambridge, and performed under a li-
cence granted by the UK Home Office. The generation of
mice expressing an Mbd3 exon 1 floxed allele (hereafter
referred to as flox) has been described [45]. Nestin-Cre
(N-Cre) expressing mice were a gift from Francois
Tronche and have been previously described [22]. N-Cre
mice were mated with Mbd3flox/+ mice to generateN-Cre:Mbd3flox/+ mice. The genotypes of all offspring
were recorded at several embryonic stages (Table 1).
The N-Cre:Mbd3flox/flox genotype is embryonic lethal
in the majority of cases; any mice with this genotype
born alive died within 24 h of birth (Table 1). No
difference was observed in the expected ratios for the
other genotypes, including N-Cre:Mbd3flox/+. For the pur-
poses of this paper, therefore, we will refer to all mice
with the N-Cre:Mbd3flox/flox genotype as conditional
knockouts (cKO) or mutant and all other genotypes as
WT. Both male and female mice were used in this study.
For neuronal output and birth dating experiments, preg-
nant mice were injected with a single dose of BrdU
(40 mg/kg, Sigma, Gillingham, UK) at E13.5 or 15.5.
Immunohistochemistry
Whole heads (E12.5 and E14.5 embryos) or dissected
whole brains (E16.5 and E18.5 embryos) were fixed in
4% paraformaldehyde (Sigma, Gillingham, UK) for 24 h
(for E12.5 and E14.5 embryos) or 48 h (for E16.5 and
E18.5 embryos) and then switched to a 30% sucrose/PBS
solution. Coronal sections were cut at a thickness of
10 μm and sagittal sections at a thickness of 4 μm. Sec-
tions from wild-type and mutant embryos were mounted
on the same slide so that the wild-type section could act
as a positive control for the mutant section during
antibody staining.
MBD3 staining was performed using a Ventana
Discovery® (Ventana Medical Systems Inc., Tuscon, AZ,
USA) according to the manufacturer’s instructions. Both
the primary (goat anti-MBD3, 1:100, sc-9402, Santa Cruz
Biotechnologies, Santa Cruz, CA, USA) and the second-
ary (biotinylated anti-goat, 1:500, Vector Laboratories,
Peterborough, UK) antibodies were titrated manually.
Haematoxylin was used as a counterstain.
Immunofluorescent staining was performed on cor-
onal frozen sections with antigen retrieval by boiling
three times for <1 min in 0.01 M citrate buffer (pH 6.0)
containing 0.05% Tween-20. For slides stained using
Table 2 Primers used for gene expression analyses
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performed. Primary antibodies used are as follows:
rat anti-BrdU, 1:100, ab6326, Abcam (Cambridge,
UK); rabbit anti-BRN2, 1:100, sc-6029, Santa Cruz
Biotechnology (Santa Cruz, CA, USA); rabbit anti-
Caspase-3 (cleaved), 1:100, 9664S, Cell Signalling
Technologies (Hitchin, UK); rat anti-BCL11B, 1:500,
ab18465, Abcam (Cambridge, UK); rabbit anti-CDP
(CUX1), 1:200, sc-13024, Santa Cruz Biotechnology
(Santa Cruz, CA, USA); rat anti-phosphorylated Histone
H3, 1:500, ab10543, Abcam (Cambridge, UK); rabbit
anti-Ki67, 1:100, Vector Laboratories (Peterborough, UK);
rabbit anti-PAX6, 1:500, ab2237; Millipore (Watford, UK);
mouse anti-Reelin, 1:100, mab5384, Millipore (Watford,
UK); mouse anti-SATB2, 1:100, ab51502, Abcam
(Cambridge, UK); rabbit anti-S100β, 1:100, Z0311,
Dako Cytomation (Ely, UK); rabbit anti-TBR1, 1:250,
ab31940, Abcam (Cambridge, UK); rabbit anti-EOMES,
1:500, ab23345, Abcam (Cambridge, UK); mouse anti-
TuJ1, 1:50, MMS-435P, Covance (Maidenhead, UK). Sec-
ondary antibodies used are as follows: Cy3 conjugated
donkey anti-rat, 712-165-153, Jackson Immunoresearch
Laboratories Inc. (Newmarket, UK); Alexa-Fluor© - 488
(A21206) or 555 (A31572) conjugated donkey anti-
rabbit and Alexa-Fluor© - 488 (A21202), 555 (A31570)
or 647 (A31571) conjugated donkey anti-mouse, Life
Technologies (Paisley, UK).
Image acquisition and analysis
MBD3-stained sections were visualised using a Zeiss
axioimager bright field microscope (Welwyn Garden
City, UK). Sections with immunofluorescent staining
were visualised using a Leica Microsystems SP5 TCS
confocal microscope (Leica Microsystems, Milton
Keynes, UK). Quantification of the number of positively
stained cells for each antibody was carried out on con-
focal microscope images with ImageJ software and the
ITCN plug-in [25]. One or two matched WTand cKO lit-
termates from two to three different litters were chosen
for analysis. Three non-consecutive slides from each
sample were chosen for staining. A schematic showing
where in the brain each picture was taken is shown in
Additional file 1: Figure S1A. The three sections chosen
per mouse were rostral, middle and caudal sections; the
results are presented as each area separately (Figure 1),
averaged mid-cortical sections only (Figures 2B,D and 6)
or averaged over all three areas (Figures 2F,G, 4, and 7).
The images shown are either anterior (Figure 2E), middle
(Figures 1, 2A,C, 3, 6, and 9) or caudal (Figures 4 and 7).
Briefly, an intensity threshold for positive staining was
chosen for each antibody. A region of interest that was
100 μm along the cortical length was designated (either
the whole cortex, cortical plate, VZ or non-VZ, as indi-
cated), and all cells with staining above the thresholdwere counted. For the BrdU/PAX6 staining, a very high
threshold for BrdU positive staining was chosen so as to
exclude weakly positive basal progenitors from the
counts (indicated in the figure as BrdU++). Measure-
ments are reported as mean ± the standard deviation.
GraphPad QuickCalcs online tool (http://www.graphpad.
com/quickcalcs/index.cfm) was used to for all statistical
analysis. Grubb’s test was used to detect and remove statis-
tical outliers. An unpaired two-tailed student’s t-test was
used to determine the statistical differences between WT
and Mbd3 cKO.
Cell cycle analysis
Cortices were dissected from E14.5 and E16.5 embryos
and a single-cell suspension made before fixing in 70%
ethanol for 30 min. The fixed cells were washed twice in
PBS +10% foetal calf serum and re-suspended in 1 ml
PBS+ 10% serum. An equal volume of re-suspended cells
was taken from each sample and pooled. This pool was
the split into three parts: a primary antibody only con-
trol, a secondary antibody only control and a propidium
iodide only control. The samples were stained with a
1:500 dilution of anti-PAX6 antibody and an AlexaFluor
647 conjugated anti-rabbit secondary following the Abcam
direct flow cytometry protocol (http://www.abcam.com/
index.html?pageconfig=resource&rid=11380; Cambridge,
UK). Before analysis, 200 μl propidium iodide (50 μg/ml,
Sigma, Gillingham, UK) was added to each sample and
controls. Flow cytometry was performed using a CyAn
Table 3 Primers used for ChIP
Primer name Sequence (5′ to 3′)
Nhlh1 -455 F AGGGAGGACCTTCAGGTTAC
Nhlh1 -455R TTTCATTCTGAGTCCCAGCG
Nhlh1 -298 F TGCTACCTCTAGTGTGGGAG
Nhlh1 -298R AATAGAGAGCTGGGGAAGGG
Nhlh1 145 F CCCTTTTGCCTAGGCCTTAC
Nhlh1 145R CTCAAGGGTCATCTGTCTGC
Nhlh1 314 F GACAGATGACCCTTGAGCAG
Nhlh1 314R ATGCTGCCCAAAGAATCCAA
Nhlh1 871 F ACATGGATGGGAAATGCTCC
Nhlh1 871R CACCAGCATCTGACACCTAC
Nhlh1 1522 F GAGGCTGAGGGATTGTGAAG
Nhlh1 1522R CCTTCTGCACCCTTGTTTCT
Nhlh1 2906 F TGTCTCGAAGGACTTCACCT
Nhlh1 2906R AGCCGAACTTGGCTTCATAG
Nhlh1 3683 F CTCCTACCTGAACCATGTGC
Nhlh1 3683R AGGGAAATGGGGAGAATCCA
Nhlh2 -4520 F CGATGCCTCAACACATACCA
Nhlh2 -4520R TACCCACTCACAGACACACT
Nhlh2 -824 F TTTGGGACTGGAGGTCATCT
Nhlh2 -824R CCCATCCTAACACGTGAGTG
Nhlh2 418 F AGAGGCAACCTTAAGCCCTA
Nhlh2 418R GGGACGATTCCTCCACTTTC
Nhlh2 2907 F GAGCTCCGCAAACTACTACC
Nhlh2 2907R TCAAGTGTCTCTGGGCAAAC
Nhlh2 4798 F CCAGCCTGGGATGGTATAGA
Nhlh2 4798R CTCCTTAGCCCCGAGTTTTC
NeuroD1 -1150 F AACCATTCCTCCTCCTCCTC
NeuroD1 -1150R CTGTTTCCCTTTCTGGGGAC
NeuroD1 -619 F AAGGTTGAGTCAAGGCTGTG
NeuroD1 -619R GGTGGCTGGCTTCTAATCTC
NeuroD1 -338 F AAGCAGTCTTCAGGCTAGGA
NeuroD1 -338R ATTAACCCTTTGTGGCAGCA
NeuroD1 328 F ATTTGTGGAGTCGGTTGTCC
NeuroD1 328R GAGTGCTGGGACTCATTACG
NeuroD1 830 F TGCTACCTGTTACTGTCCCA
NeuroD1 830R GGCTTTTCAAAGTTCGCCTC
NeuroD1 1450 F GTGAGTTGGGAGTGACTTGG
NeuroD1 1450R GTCCACTGCAAAATGGATGC
NeuroD1 2258 F AATAGAGACACTGCGCTTGG
NeuroD1 2258R CAGGGGACTGGTAGGAGTAG
NeuroD1 2658 F TGCCTTTACCATGCACTACC
NeuroD1 2658R GTTGTCTATGGGGATCTCGC
NeuroD1 4271 F AGCTTGTCCTGTGCTTAGTC
NeuroD1 4271R TAAAACAGAGGCGAGGTCTG
Table 3 Primers used for ChIP (Continued)
NeuroD2 -1838 F GACTTCCTAGTTGCAGAGCC
NeuroD2 -1838R GAAAGAAGGTCCAAAGGCCA
NeuroD2 -450 F GGTGCCAGCATCTACCTATG
NeuroD2 -450R CATTTCCCTGTCTCCAGGTC
NeuroD2 428 F CCGTGTTCTCTCTCCCATTG
NeuroD2 428R GTGGGAAAAGGTCACAGGTT
NeuroD2 1388 F CACTCTGTGCTGTCTGTCTC
NeuroD2 1388R GGATCTCTTCTCCTCCACGA
NeuroD2 3082 F CACCCTAACACGAATCTCCG
NeuroD2 3082R ATGCGTTTTCTCTCCGATCC
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UK). A gate was set to PAX6-positive cells only. The data
were then exported into FlowJo software (Tree Star Inc.,
Ashland, OR, USA), and the cell cycle was analysed using
the software’s pre-set Dean-Jett-Fox method. An unpaired
two-tailed t-test using the GraphPad QuickCalcs online
tool was performed to detect significant differences be-
tween genotypes.
LCM and RNA extraction
Coronal brain sections of 4 WT and 4 cKO E12.5, E14.5
and E16.5 embryos were used for laser capture microdis-
section using a Zeiss (Welwyn Garden City, UK) PALM
Microbeam laser capture system as per the manufac-
turer’s instructions. The VZ from the left and right
hemispheres from 3–4 sections per slide were dissected
into adhesive cap tubes and incubated overnight at 55°C
in 75 μl Proteinase K buffer (100 mM Tris pH7.5,
200 mM NaCl, 2 mM EDTA, 1% SDS), 65 μl water and
250 μg Proteinase K. The samples were treated with
3.75 μl of DNAseI and 15 μl buffer RDD from the RNAse-
free DNAse Kit (Qiagen) for 10 minutes at room
temperature. RNA was extracted using the Qiagen RNeasy
Plus micro kit, as per the manufacturer’s instructions.
Microarray and data analysis
RNA amplification (Ovation pico WTA system, Nugen,
Bemmel, The Netherlands) and hybridization to
MouseWG-6 vs. 2 Illumina arrays was performed by
Cambridge Genomic Services (University of Cambridge,
Department of Pharmacology). Expression data were pre-
processed using the R package ‘lumi’ [46]. A variance sta-
bilising transformation, robust spline normalisation and
QC were performed on the expression data. To test for
differential expression, the statistical method limma was
used [47]. Multiple testing correction based on the false
discovery rate (FDR) was performed. F-statistics from the
Bayesian adjusted linear models were used to determine
significant differential expression. The FDR method used
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was +/− 0.5 (ArrayExpress accession number E-MTAB-
2778). The software programme STEM was used to
cluster and analyse the gene expression data [32]. The
STEM programme calculates the significance of a cluster
based on the ratio of the number of assigned genes versus
the number of expected genes to a profile. The P value
threshold used was 0.05, which was adjusted for multiple
testing using the Bonferroni correction. GO analyses
were performed using DAVID (http://david.abcc.ncifcrf.
gov/summary.jsp). DAVID uses a modified Fisher Exact
p-Value and the threshold used was 0.05.
qRTPCR
RNA from LCM was used to make cDNA using the
transcriptor first-strand cDNA synthesis kit (Roche,
West Sussex, UK) following the manufacturer’s instruc-
tions. The resulting cDNA was used in triplicate SYBR
green reactions (Life Technologies, Paisley, UK). Primers
are listed in Table 2. Ppia expression was used as a control.
Relative expression values are reported as mean ± the
standard deviation. For comparisons between cKO and
WT, an unpaired two-sided t-test was performed.
Chromatin immunoprecipitation
Cortices were dissected from E14.5 or E16.5 brains. Two
(E16.5) to three (E14.5) cortices of like genotype were
dissociated together in 1 ml of PBS using a Dounce
homogeniser. Formaldehyde was then added to a final
concentration of 1% and allowed to fix for 10 min.
Glycine was then added to a final concentration of
0.125 M. ChIP was then performed using standard
methods, as described (Reynolds et al. [17]), using an
anti-Mbd3 antibody (rabbit anti-Mbd3, A302-528A,
Bethyl Laboratories, Montgomery, TX, USA) or a rabbit
IgG control (Invitrogen, Carlsbad, CA, USA). ChIPs were
performed a minimum of three times, and qPCR was
carried out in triplicate using primers indicated in Table 3.
Additional files
Additional file 1: Figure S1. Location of pictures presented and MBD3
expression at E16.5. (A) Schematic representation of a sagittal mouse
brain showing where rostral, middle and caudal sections were taken.
Below are schematics of coronal rostral, middle and caudal sections
showing where the displayed pictures were taken. (B) Immunostaining
for MBD3 on sagittal sections of three WT and three MBD3 cKO brains at
E16.5. Scale bar = 100 μm. (C) Immunostaining for TuJ1 on posterior
coronal sections of WT and MBD3 cKO brains at E12.5, E14.5 and E16.5
taken at low magnification (5×).
Additional file 2: Figure S2. No difference in levels of apoptosis
detectable in Mbd3 cKO and WT embryonic brain. (A) Representative
immunostaining of E16.5 brain sections for activated (cleaved) CASPASE-3
(green) alone (left panel) and counterstained with DAPI (blue, right panel).
(B) Quantification of the mean number of positive cells observed per
section at E14.5, 16.5 and E18.5. N = 3 to 5, scale bar = 100 μm.Additional file 3: Figure S3. Mbd3cKO embryos have altered cell cycle
distribution at E14.5. (A, B) Average percentage of PAX6+ cells in each
phase of the cell cycle at 16.5 (A, N = 2 to 12) and E14.5 (B, N = 5 to 6)
*P < 0.05. Error bars represent st. dev.
Additional file 4: Figure S4. No difference in CUX1 staining between WT
and MBD3 cKO embryonic brains at E18.5. Representative immunostaining of
E18.5 coronal brain sections for CUX1 (green) from WT (left) and MBD3 cKO
(right) embryos. Scale bar = 100 μm.
Additional file 5: Figure S5. No detectable difference in Cajal-Retzius/
layer 1 marginal zone neurons between Mbd3 cKO and wild-type
embryonic brain. Representative immunostaining of E16.5 brain sections for
Reelin (green) counterstained with DAPI (Blue) from wild-type (A) and cKO
(B) embryos.
Additional file 6: Table S1. List of microarray genes in STEM cluster 35.
Additional file 7: Table S3. List of microarray genes in STEM cluster 39.
Additional file 8: Table S2. GO term analysis of genes in STEM cluster 35.
Additional file 9: Table S4. GO term analysis of genes in STEM cluster 39.
Additional file 10: Table S5. List of microarray genes in STEM cluster 28.
Additional file 11: Table S7. List of microarray genes in STEM cluster 29.
Additional file 12: Table S6. GO term analysis of genes in STEM
cluster 28.
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